Re: Zenith Updates

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

chicagoest

Rank: President [?]

Points: 1974 [?]

Votes: 20 Score: 3.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Zenith Updates

in response to

Re: Zenith Updates

BearDownAZ

posted on Feb 02, 2016 07:40PM

BDAZ

Thanks for sharing that information.

I am trying my best to digest these technical reports but usually get lost along the way - science and medicene are not my forte. I can grasp the MACE endpoints of the BetonMace trial, and the claim that ZEN-3694 inhibits resistance to therapies. Both ZEN-3694 and RVX-222 Synergize with other treatments to achieve their outcomes. Are Zen-3694 and RVX-222 additives that must always be used with other therapies? Must they be specifically designed for each combination? Can BET Bromodomain Inhibition be targeted with any therapy? Can it be successful independently as in reverse cholesteral transport? I'm just trying to take it all in.